Inhaled Drug Developer Avalyn Files for U.S. IPO

Avalyn Pharma seeks Nasdaq listing to fund clinical trials for pulmonary fibrosis treatments.

Apr. 10, 2026 at 4:23pm

Got story updates? Submit your updates here. ›

A high-end, photorealistic studio still-life featuring a collection of sleek, premium medical devices and drug packaging arranged elegantly on a clean, monochromatic background, conceptually representing Avalyn Pharma's innovative inhaled therapies for pulmonary fibrosis.Avalyn Pharma's innovative inhaled drug candidates for pulmonary fibrosis aim to provide new hope for patients struggling with this debilitating lung disease.Boston Today

Avalyn Pharma, a Boston-based biotech company focused on developing inhaled therapeutics for pulmonary fibrosis, has filed paperwork with the SEC for an initial public offering on the Nasdaq stock exchange.

Why it matters

Pulmonary fibrosis is a chronic and progressive lung disease with limited treatment options, so Avalyn's inhaled drug candidates could provide new hope for patients if successful in clinical trials. The IPO would give Avalyn the funding needed to advance its pipeline and potentially bring innovative therapies to market.

The details

Avalyn Pharma submitted its S-1 filing on Wednesday, officially kicking off the process to go public on the Nasdaq. The company is developing inhaled drug treatments for pulmonary fibrosis, a debilitating lung condition marked by scarring and stiffening of lung tissue that makes it difficult to breathe.

  • Avalyn Pharma filed its S-1 paperwork with the SEC on Wednesday, April 10, 2026.

The players

Avalyn Pharma

A Boston-based biotech company focused on developing inhaled therapeutics for pulmonary fibrosis.

Got photos? Submit your photos here. ›

What’s next

Avalyn Pharma will now go through the SEC review process before pricing and launching its Nasdaq IPO, which could take several months.

The takeaway

Avalyn's IPO filing highlights the continued investor interest in innovative treatments for pulmonary fibrosis, a devastating lung disease with high unmet medical need. If successful, the company's inhaled drug candidates could provide new hope for patients struggling with this chronic condition.